---
title: "XOMA Royalty Corporation (XOMA.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/XOMA.US.md"
symbol: "XOMA.US"
name: "XOMA Royalty Corporation"
industry: "Biotechnology"
datetime: "2026-05-19T21:45:55.431Z"
locales:
  - [en](https://longbridge.com/en/quote/XOMA.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/XOMA.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/XOMA.US.md)
---

# XOMA Royalty Corporation (XOMA.US)

## Company Overview

XOMA Royalty Corporation operates as a biotech royalty aggregator in the United States, Switzerland, the Asia Pacific, and Australia. It has a portfolio of economic rights to future potential milestone and royalty payments associated with commercial products and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to sponsors or developers; and acquires milestone and royalty revenue streams on late-stage clinical assets and commercial assets. It has a portfolio with various assets.

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | US Market |
| Website | [www.xoma.com](https://www.xoma.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: C
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-19T04:30:12.000Z

**Overall: C (0.43)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Ranking | 118 / 386 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Blend - Stocks in which the company has both growth and mature businesses.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: C

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 13.16% |  |
| Net Profit YoY | 271.58% |  |
| P/B Ratio | 5.63 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 522208489.20 |  |
| Revenue | 48555000.00 |  |

#### Multi Score Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 22.47% | A |
| Profit Margin | 69.63% | A |
| Gross Margin | 99.60% | A |
| Revenue YoY | 13.16% | B |
| Net Profit YoY | 271.58% | A |
| Total Assets YoY | 27.78% | A |
| Net Assets YoY | 33.40% | A |
| Cash Flow Margin | 34.09% | D |
| OCF YoY | 13.16% | B |
| Turnover | 0.20 | D |
| Gearing Ratio | 58.47% | D |

```chart-data:radar
{
  "title": "Longbridge Financial Score - XOMA Royalty Corporation",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "13.16%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "271.58%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "5.63",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "522208489.20",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "48555000.00",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "C",
      "indicators": [
        {
          "name": "ROE",
          "value": "22.47%",
          "rating": "A"
        },
        {
          "name": "Profit Margin",
          "value": "69.63%",
          "rating": "A"
        },
        {
          "name": "Gross Margin",
          "value": "99.60%",
          "rating": "A"
        },
        {
          "name": "Revenue YoY",
          "value": "13.16%",
          "rating": "B"
        },
        {
          "name": "Net Profit YoY",
          "value": "271.58%",
          "rating": "A"
        },
        {
          "name": "Total Assets YoY",
          "value": "27.78%",
          "rating": "A"
        },
        {
          "name": "Net Assets YoY",
          "value": "33.40%",
          "rating": "A"
        },
        {
          "name": "Cash Flow Margin",
          "value": "34.09%",
          "rating": "D"
        },
        {
          "name": "OCF YoY",
          "value": "13.16%",
          "rating": "B"
        },
        {
          "name": "Turnover",
          "value": "0.20",
          "rating": "D"
        },
        {
          "name": "Gearing Ratio",
          "value": "58.47%",
          "rating": "D"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | 26.20 | 45/386 | 34.10 | 32.03 | 25.49 |
| PB | 5.63 | 336/386 | 5.71 | 4.08 | 3.60 |
| PS (TTM) | 10.75 | 169/386 | 9.35 | 7.60 | 6.87 |
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Kiniksa Pharmaceuticals (KNSA.US) | B | A | A | B | A | A |
| 02 | Arbutus Pharma (ABUS.US) | A | A | A | A | B | A |
| 03 | Rigel Pharma (RIGL.US) | A | A | B | A | B | A |
| 04 | Spero Therap (SPRO.US) | A | A | B | A | B | A |
| 05 | CapForce Inc. (CFOR.US) | B | A | A | A | B | A |

## Institutional View

### Analyst Rating Distribution

> As of 2026-05-06T04:00:00.000Z

Total Analysts: **3**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 1 | 33% |
| Hold | 2 | 67% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 41.54 |
| Highest Target | 50.00 |
| Lowest Target | 39.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/XOMA.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/XOMA.US/norm.md)
- [Related News](https://longbridge.com/en/quote/XOMA.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/XOMA.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**